Get the Stockscreener App
229.23
2.94%
6.54
Ascendis Pharma A S stock is traded at $229.23, with a volume of 815.73K.
It is up +2.94% in the last 24 hours and down -12.11% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$222.69
Open:
$225.08
24h Volume:
815.73K
Relative Volume:
1.29
Market Cap:
$15.08B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
25.83
EPS:
8.8733
Net Cash Flow:
$50.57M
1W Performance:
+0.60%
1M Performance:
-12.11%
6M Performance:
-5.16%
1Y Performance:
+6.73%
1-Day Range:
$223.96
$233.96
1-Week Range:
$219.52
$233.96
52-Week Range:
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
229.23 | 14.84B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Benzinga
Form 4 Ascendis Pharma A/S For: 29 September By Investing.com - Investing.com Nigeria
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
Ascendis Pharma (ASND) Could Be 28% Undervalued As It Reclaims TransCon Rights - Simply Wall Street
Enterprise value of Ascendis Pharma A/S – FWB:A710 - TradingView
Total operating expenses of Ascendis Pharma A/S – FWB:A710 - TradingView
Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk - moomoo.com
Ascendis Pharma (NASDAQ: ASND) Severs Novo Nordisk Tie To Take Full Control Of TransCon Metabolic Pipeline - foreignpolicyjournal.com
Ascendis Pharma A/S (ASND) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 - moomoo.com
Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a Potential 31.52% Upside in Biotech Sector - DirectorsTalk Interviews
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - Yahoo Finance
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs - Yahoo Finance
Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data - Simply Wall Street
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? - Yahoo Finance
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory - medwatch.com
Novo Nordisk ends $285M TransCon partnership with Ascendis, which will now develop monthly obesity drug itself - Dealroom
Ascendis Pharma: Back To Full Independence (NASDAQ:ASND) - Seeking Alpha
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says - finance.yahoo.com
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end - Investing.com
Ascendis regains obesity rights as Novo exits monthly GLP-1 deal - thepharmaletter.com
Ascendis CEO after scrapped Novo partnership: Big mistake to be dependent on Big Pharma - medwatch.com
Ascendis Pharma (ASND) Reclaims Global TransCon Rights For Obesity And Heart Disease - simplywall.st
Why Is Ascendis Pharma Stock Trading Lower on Tuesday? - TradingView
Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send? - TradingKey
Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback - Quiver Quantitative
Ascendis Pharma Cut to Outperform From Strong Buy by Raymond James - Moomoo
Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights - Investing.com
Novo still seeks a long-acting treatment after scrapped deal with Ascendis - medwatch.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis - Fierce Biotech
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback - marketscreener.com
Novo Nordisk deal ends as Ascendis (NASDAQ: ASND) takes back obesity drug rights, with more programs shifting over - Stock Titan
Novo Nordisk, Ascendis Pharma End Metabolic, Cardiovascular Partnership - marketscreener.com
Ascendis Pharma authorizes $400 million share buyback program - Investing.com
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis plans a once-monthly obesity drug after its Novo deal ends - Stock Titan
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today - benzinga.com
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup - ChartMill
Consensus Analysis | Ascendis Pharma | 2026-09-14 - Biostock
Ascendis Pharma A/S (ASND) Stock Analysis: Is the 18.6% Upside a Green Light for Investors? - DirectorsTalk Interviews
Ascendis Pharma authorizes $400 million share buyback program By Investing.com - Investing.com UK
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Nigeria
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ascendis Pharma A S Stock (ASND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO |
Sep 08 '26 |
Sale |
270.19 |
3,000 |
810,570 |
0 |
5.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):